Biotech Business - LEVAQUIN GETS FDA APPROVAL FOR 5-DAY TREATMENT OF CAP.
The U.S. Food and Drug Administration has approved a new 5-day dosage form of LEVAQUIN(R) (levofloxacin) Tablets/Injection and LEVAQUIN(R) (levofloxacin in 5% dextrose) Injection 750mg once-daily regimen to treat mild-to-severe community acquired pneumonia (CAP). With this approval, LEVAQUIN becomes the only short-course fluoroquinolone indicated to treat CAP in a 5-day regimen.
Most Popular
3 Questions No Job Seeker Ever Wants To Be Asked?
Thinking Through Uncertainty: CFOs Scrutinize Non-Financial Risk
10 Jobs That Pay $30 An Hour
Public Speaking: 7 Secrets Of Great Public Speakers
13 Job Interview Mistakes To Avoid
“In an effort to address bacterial resistance, the World Health Organization (WHO) Antimicrobial Resistance Guidelines have called for aggressive, short-courses of therapy,” said Thomas M. File, …
Read the rest of this article with a Free Trial at HighBeam Research.
